Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Inventory (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Change in Inventory for 11 consecutive years, with -$609000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory rose 2.87% to -$609000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.1 million, a 152.85% decrease, with the full-year FY2025 number at -$382000.0, down 107.92% from a year prior.
  • Change in Inventory was -$609000.0 for Q4 2025 at Aytu Biopharma, up from -$1.1 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $2.1 million in Q3 2022 to a low of -$7.2 million in Q2 2021.
  • A 5-year average of -$115263.2 and a median of $178000.0 in 2021 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: soared 1082.02% in 2022, then plummeted 216.17% in 2025.
  • Aytu Biopharma's Change in Inventory stood at $390000.0 in 2021, then crashed by 79.74% to $79000.0 in 2022, then surged by 765.82% to $684000.0 in 2023, then plummeted by 191.67% to -$627000.0 in 2024, then increased by 2.87% to -$609000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Change in Inventory are -$609000.0 (Q4 2025), -$1.1 million (Q3 2025), and $518000.0 (Q2 2025).